|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL36A |
Gene summary for RPL36A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL36A | Gene ID | 6173 |
| Gene name | ribosomal protein L36a | |
| Gene Alias | L36A | |
| Cytomap | Xq22.1 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | J3KQN4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6173 | RPL36A | GSM4909280 | Human | Breast | Precancer | 1.28e-03 | 1.05e-01 | 0.0305 |
| 6173 | RPL36A | GSM4909281 | Human | Breast | IDC | 1.48e-32 | -4.24e-01 | 0.21 |
| 6173 | RPL36A | GSM4909282 | Human | Breast | IDC | 4.15e-09 | -1.68e-01 | -0.0288 |
| 6173 | RPL36A | GSM4909285 | Human | Breast | IDC | 5.31e-39 | -4.30e-01 | 0.21 |
| 6173 | RPL36A | GSM4909286 | Human | Breast | IDC | 1.54e-18 | -2.15e-01 | 0.1081 |
| 6173 | RPL36A | GSM4909287 | Human | Breast | IDC | 8.15e-48 | -8.65e-01 | 0.2057 |
| 6173 | RPL36A | GSM4909288 | Human | Breast | IDC | 6.59e-11 | -7.09e-01 | 0.0988 |
| 6173 | RPL36A | GSM4909289 | Human | Breast | IDC | 1.31e-02 | -3.60e-01 | 0.1064 |
| 6173 | RPL36A | GSM4909290 | Human | Breast | IDC | 2.01e-21 | -4.58e-01 | 0.2096 |
| 6173 | RPL36A | GSM4909292 | Human | Breast | IDC | 1.84e-06 | -7.27e-01 | 0.1236 |
| 6173 | RPL36A | GSM4909293 | Human | Breast | IDC | 5.18e-29 | -2.67e-01 | 0.1581 |
| 6173 | RPL36A | GSM4909294 | Human | Breast | IDC | 3.86e-35 | -7.53e-01 | 0.2022 |
| 6173 | RPL36A | GSM4909296 | Human | Breast | IDC | 5.78e-35 | 3.76e-01 | 0.1524 |
| 6173 | RPL36A | GSM4909297 | Human | Breast | IDC | 4.58e-12 | 6.37e-02 | 0.1517 |
| 6173 | RPL36A | GSM4909302 | Human | Breast | IDC | 1.16e-05 | -2.96e-01 | 0.1545 |
| 6173 | RPL36A | GSM4909305 | Human | Breast | IDC | 1.30e-08 | -1.44e-01 | 0.0436 |
| 6173 | RPL36A | GSM4909307 | Human | Breast | IDC | 1.43e-32 | -5.46e-01 | 0.1569 |
| 6173 | RPL36A | GSM4909308 | Human | Breast | IDC | 1.23e-49 | -6.30e-01 | 0.158 |
| 6173 | RPL36A | GSM4909309 | Human | Breast | IDC | 1.24e-27 | -6.82e-01 | 0.0483 |
| 6173 | RPL36A | GSM4909311 | Human | Breast | IDC | 2.36e-94 | 6.05e-01 | 0.1534 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
| GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
| GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
| GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
| GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
| GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
| GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
| GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
| GO:000218132 | Liver | Cyst | cytoplasmic translation | 70/496 | 148/18723 | 9.01e-71 | 3.85e-67 | 70 |
| GO:00021818 | Lung | IAC | cytoplasmic translation | 85/2061 | 148/18723 | 3.11e-43 | 1.85e-39 | 85 |
| GO:000218113 | Lung | AIS | cytoplasmic translation | 85/1849 | 148/18723 | 5.48e-47 | 3.19e-43 | 85 |
| GO:000218133 | Lung | MIAC | cytoplasmic translation | 73/967 | 148/18723 | 4.84e-54 | 2.48e-50 | 73 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301029 | Prostate | Tumor | Ribosome | 104/1791 | 167/8465 | 3.53e-31 | 5.84e-29 | 3.62e-29 | 104 |
| hsa0517129 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
| hsa0301037 | Prostate | Tumor | Ribosome | 104/1791 | 167/8465 | 3.53e-31 | 5.84e-29 | 3.62e-29 | 104 |
| hsa0517137 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
| hsa0301012 | Stomach | GC | Ribosome | 64/708 | 167/8465 | 2.58e-27 | 8.26e-25 | 5.81e-25 | 64 |
| hsa0517112 | Stomach | GC | Coronavirus disease - COVID-19 | 71/708 | 232/8465 | 2.32e-23 | 3.72e-21 | 2.62e-21 | 71 |
| hsa0301013 | Stomach | GC | Ribosome | 64/708 | 167/8465 | 2.58e-27 | 8.26e-25 | 5.81e-25 | 64 |
| hsa0517113 | Stomach | GC | Coronavirus disease - COVID-19 | 71/708 | 232/8465 | 2.32e-23 | 3.72e-21 | 2.62e-21 | 71 |
| hsa0301021 | Stomach | CAG with IM | Ribosome | 63/640 | 167/8465 | 5.86e-29 | 1.86e-26 | 1.31e-26 | 63 |
| hsa0517121 | Stomach | CAG with IM | Coronavirus disease - COVID-19 | 68/640 | 232/8465 | 9.36e-24 | 1.49e-21 | 1.04e-21 | 68 |
| hsa0301031 | Stomach | CAG with IM | Ribosome | 63/640 | 167/8465 | 5.86e-29 | 1.86e-26 | 1.31e-26 | 63 |
| hsa0517131 | Stomach | CAG with IM | Coronavirus disease - COVID-19 | 68/640 | 232/8465 | 9.36e-24 | 1.49e-21 | 1.04e-21 | 68 |
| hsa0301041 | Stomach | CSG | Ribosome | 64/633 | 167/8465 | 3.70e-30 | 1.17e-27 | 8.41e-28 | 64 |
| hsa0517141 | Stomach | CSG | Coronavirus disease - COVID-19 | 69/633 | 232/8465 | 8.56e-25 | 1.35e-22 | 9.74e-23 | 69 |
| hsa0301051 | Stomach | CSG | Ribosome | 64/633 | 167/8465 | 3.70e-30 | 1.17e-27 | 8.41e-28 | 64 |
| hsa0517151 | Stomach | CSG | Coronavirus disease - COVID-19 | 69/633 | 232/8465 | 8.56e-25 | 1.35e-22 | 9.74e-23 | 69 |
| hsa0301061 | Stomach | CAG | Ribosome | 61/368 | 167/8465 | 2.85e-41 | 8.23e-39 | 6.59e-39 | 61 |
| hsa0517161 | Stomach | CAG | Coronavirus disease - COVID-19 | 63/368 | 232/8465 | 7.19e-34 | 1.04e-31 | 8.32e-32 | 63 |
| hsa0301071 | Stomach | CAG | Ribosome | 61/368 | 167/8465 | 2.85e-41 | 8.23e-39 | 6.59e-39 | 61 |
| hsa0517171 | Stomach | CAG | Coronavirus disease - COVID-19 | 63/368 | 232/8465 | 7.19e-34 | 1.04e-31 | 8.32e-32 | 63 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL36A | SNV | Missense_Mutation | novel | c.278G>A | p.Arg93Gln | p.R93Q | protein_coding | tolerated(0.38) | benign(0.022) | TCGA-A2-A4S2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
| RPL36A | SNV | Missense_Mutation | c.50N>T | p.Tyr17Phe | p.Y17F | protein_coding | tolerated_low_confidence(0.43) | benign(0.076) | TCGA-AQ-A1H3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | ||
| RPL36A | SNV | Missense_Mutation | c.20N>T | p.Ser7Phe | p.S7F | protein_coding | deleterious_low_confidence(0.04) | benign(0.003) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | ||
| RPL36A | SNV | Missense_Mutation | novel | c.119N>C | p.Val40Ala | p.V40A | protein_coding | deleterious(0.02) | benign(0.331) | TCGA-AJ-A3NC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPL36A | SNV | Missense_Mutation | novel | c.344N>A | p.Ser115Tyr | p.S115Y | protein_coding | tolerated(0.21) | probably_damaging(0.917) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPL36A | SNV | Missense_Mutation | c.118G>A | p.Val40Ile | p.V40I | protein_coding | tolerated(0.31) | benign(0.178) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RPL36A | SNV | Missense_Mutation | c.408N>T | p.Lys136Asn | p.K136N | protein_coding | deleterious(0.01) | possibly_damaging(0.622) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RPL36A | SNV | Missense_Mutation | c.118N>A | p.Val40Ile | p.V40I | protein_coding | tolerated(0.31) | benign(0.178) | TCGA-AP-A1DM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| RPL36A | SNV | Missense_Mutation | novel | c.325G>A | p.Val109Ile | p.V109I | protein_coding | tolerated(0.1) | benign(0.233) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPL36A | SNV | Missense_Mutation | novel | c.269N>T | p.Pro90Leu | p.P90L | protein_coding | tolerated(0.08) | benign(0.329) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |